These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. Iwanaga Y; Aoyama T; Kihara Y; Onozawa Y; Yoneda T; Sasayama S J Am Coll Cardiol; 2002 Apr; 39(8):1384-91. PubMed ID: 11955860 [TBL] [Abstract][Full Text] [Related]
5. Cardiac remodeling and failure From molecules to man (Part II). Fedak PW; Verma S; Weisel RD; Li RK Cardiovasc Pathol; 2005; 14(2):49-60. PubMed ID: 15780796 [TBL] [Abstract][Full Text] [Related]
6. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Mukherjee R; Herron AR; Lowry AS; Stroud RE; Stroud MR; Wharton JM; Ikonomidis JS; Crumbley AJ; Spinale FG; Gold MR Am J Cardiol; 2006 Feb; 97(4):532-7. PubMed ID: 16461051 [TBL] [Abstract][Full Text] [Related]
7. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure]. Yang YJ; Zhang X; Zhu WL; Huang Y Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324 [TBL] [Abstract][Full Text] [Related]
8. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling. Wei Y; Cui C; Lainscak M; Zhang X; Li J; Huang J; Zhang H; Zheng Z; Hu S J Cell Mol Med; 2011 Apr; 15(4):773-82. PubMed ID: 20219015 [TBL] [Abstract][Full Text] [Related]
9. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Spinale FG; Coker ML; Bond BR; Zellner JL Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226 [TBL] [Abstract][Full Text] [Related]
10. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. Fielitz J; Leuschner M; Zurbrügg HR; Hannack B; Pregla R; Hetzer R; Regitz-Zagrosek V J Mol Med (Berl); 2004 Dec; 82(12):809-20. PubMed ID: 15558223 [TBL] [Abstract][Full Text] [Related]
12. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Coker ML; Thomas CV; Clair MJ; Hendrick JW; Krombach RS; Galis ZS; Spinale FG Am J Physiol; 1998 May; 274(5):H1516-23. PubMed ID: 9612358 [TBL] [Abstract][Full Text] [Related]
13. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Li YY; McTiernan CF; Feldman AM Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225 [TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176 [TBL] [Abstract][Full Text] [Related]
15. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Deschamps AM; Spinale FG Cardiovasc Res; 2006 Feb; 69(3):666-76. PubMed ID: 16426590 [TBL] [Abstract][Full Text] [Related]
16. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Peterson JT; Li H; Dillon L; Bryant JW Cardiovasc Res; 2000 May; 46(2):307-15. PubMed ID: 10773235 [TBL] [Abstract][Full Text] [Related]
17. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092 [TBL] [Abstract][Full Text] [Related]
18. Temporal changes in myocardial collagen, matrix metalloproteinases, and their tissue inhibitors in the left ventricular myocardium in experimental chronic mitral regurgitation in rodents. Corporan D; Onohara D; Hernandez-Merlo R; Sielicka A; Padala M Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1269-H1278. PubMed ID: 30141979 [TBL] [Abstract][Full Text] [Related]
19. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair. Hsu CP; Huang CY; Wang JS; Sun PC; Shih CC Ann Thorac Surg; 2008 Oct; 86(4):1243-9. PubMed ID: 18805169 [TBL] [Abstract][Full Text] [Related]
20. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Spinale FG; Coker ML; Thomas CV; Walker JD; Mukherjee R; Hebbar L Circ Res; 1998 Mar; 82(4):482-95. PubMed ID: 9506709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]